Literature DB >> 24519479

Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit.

Bryan M Bishop1, John J Bon, Tamara L Trienski, Timothy R Pasquale, Bradley R Martin, Thomas M File.   

Abstract

BACKGROUND: Utilizing procalcitonin (PCT) levels to limit antimicrobial overuse would be beneficial from a humanistic and economic perspective.
OBJECTIVE: To assess whether introducing PCT at a teaching hospital reduced antimicrobial exposure in critically ill patients.
METHODS: Patients wereadmitted to the intensive care unit (ICU) for >72 hours with sepsis and/or pneumonia. PCT levels were drawn on admission to the ICU or with new suspected infection, with at least 1 PCT level being drawn at least 48 hours later. Patients were matched in a 1:1 fashion to historical patients on age, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, gender, and primary diagnosis. The primary outcome was duration of initial antimicrobial exposure defined as days from initiation of antimicrobial therapy to the intentional discontinuation of therapy by the physician. Secondary end points included length of stay, readmission to the hospital, and relapse of infection.
RESULTS: There were 50 patients in the PCT group and 50 patients in the historical group. The initial duration of antimicrobials was 10 (±4.9) days compared with 13.3 (±7.2), which was statistically significant (P = .0238). The duration of stay in the hospital (13.5 compared with 17.8 days; P = .0299), readmission to the hospital (9 compared with 17; P = .055), and relapse of infection (3 compared with 11; P = .02) were seen less in the PCT group compared with controls.
CONCLUSION: Introducing PCT levels resulted in a shorter duration of initial antimicrobial therapy and was not associated with adverse treatment outcomes.

Entities:  

Keywords:  antibiotic consumption; bacterial pneumonia; intensive care unit patients; procalcitonin; sepsis

Mesh:

Substances:

Year:  2014        PMID: 24519479     DOI: 10.1177/1060028014520957

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  8 in total

1.  Impact of Pharmacist-Led Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Pneumonia.

Authors:  Bibidh Subedi; Patricia Louzon; Kristie Zappas; Wilfred Onyia; Kevin DeBoer
Journal:  Hosp Pharm       Date:  2019-03-25

2.  Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data.

Authors:  Anne M Voermans; Janne C Mewes; Michael R Broyles; Lotte M G Steuten
Journal:  OMICS       Date:  2019-09-11

3.  Guiding Effect of Serum Procalcitonin (PCT) on the Antibiotic Application to Patients with Sepsis.

Authors:  Yu Liu; Weize Yang; Jie Wei
Journal:  Iran J Public Health       Date:  2017-11       Impact factor: 1.429

4.  Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence.

Authors:  Michael R Broyles
Journal:  Open Forum Infect Dis       Date:  2017-10-03       Impact factor: 3.835

5.  The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis.

Authors:  Janne C Mewes; Michael S Pulia; Michael K Mansour; Michael R Broyles; H Bryant Nguyen; Lotte M Steuten
Journal:  PLoS One       Date:  2019-04-23       Impact factor: 3.240

6.  Pancreatic stone protein point-of-care testing can reduce healthcare expenditure in sepsis.

Authors:  John E Schneider; Katherine Dick; Jacie T Cooper; Nadine Chami
Journal:  Health Econ Rev       Date:  2022-07-22

7.  Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?

Authors:  Matteo Bassetti; Tobias Welte; Richard G Wunderink
Journal:  Crit Care       Date:  2016-01-29       Impact factor: 9.097

8.  Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study.

Authors:  Eric Gluck; H Bryant Nguyen; Kishore Yalamanchili; Margaret McCusker; Jaya Madala; Frank A Corvino; Xuelian Zhu; Robert Balk
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.